Phased formulations of ethinylestradiol vs Medroxyprogesterone acetate
National NHS prescribing compared (Prescription Cost Analysis)
Medroxyprogesterone acetate was dispensed 73.2× as often as Phased formulations of ethinylestradiol in May 2026 — 55,709 items versus 761 in England.
761items
Phased formulations of ethinylestradiol · May 2026
NHSBSA Prescription Cost Analysis
55,709items
Medroxyprogesterone acetate · May 2026
NHSBSA Prescription Cost Analysis
Figure 1. Phased formulations of ethinylestradiol versus Medroxyprogesterone acetate: national items dispensed by month
▬ Phased formulations of ethinylestradiol · ╌ Medroxyprogesterone acetate
Source: NHSBSA Prescription Cost Analysis, to May 2026
| Measure | Phased formulations of ethinylestradiol | Medroxyprogesterone acetate |
|---|---|---|
| Items, May 2026 | 761 | 55,709 |
| Items, last 12 months | 11,106 | 719,261 |
| Net ingredient cost, May 2026 | £4,367 | £361,619 |
See the full profile for Phased formulations of ethinylestradiol or Medroxyprogesterone acetate.